No abstract available.
Vincristine*

No abstract available.
Animals ; Doxorubicin* ; Mononuclear Phagocyte System* ; Rats* ; Vincristine*

Previously unreported vacuolar changes were seen in skeletal muscles of male Sprague-Dawley rats given LD 50 doses of vincristine sulfate. Morphologic changes involving 10.20% of the muscle fibers were seen starting 4 days after vincristine administration and consist of the following: appearance of one or more centrally located vacuoles, atrophy of muscle fibers and sarcolemmal proliferation. By day 8, muscle involvement approached 100% in most sections and consisted of extensive vacuolization plus sarcolemmal proliferation without round-cell infiltrationThat myopathy may be caused by vincristine administration has been proved in rodents.(Summary)
Plants, Rats, Rats, Imbred Strains, Vacuoles, Vincristine

No abstract available.
Cyclophosphamide* ; Drug Therapy, Combination* ; Hodgkin Disease* ; Procarbazine* ; Vincristine*

OBJECTIVE: This retrospective study was performed to evaluate the role of chemotherapy in the management of patients with anaplastic astrocytoma (AA). METHODS: We compared the survival outcome among the 3 different treatment protocol groups in a single institution. A total of 86 patients (39 men and 47 women) with newly diagnosed AA after surgery were analyzed. Among them, 31 patients (36.0%) were treated with radiotherapy only (RT Group), 30 patients (34.9%) were treated with nimustine-cisplatin chemotherapy before RT (ACNU-CDDP group), and 25 patients (29.1%) were treated with procarbazine, lomustine and vincristine (PCV) chemotherapy after radiotherapy (PCV group). RESULTS: The median survival was 14.0, 30.0 and 72.0 months in RT, ACNU-CDDP, and PCV group, respectively and showed significant differences (RT vs. ACNU-CDDP; p=0.039, RT vs. PCV; 0.002, ACNU-CDDP vs. PCV; 0.045). PCV group showed less toxicity rate (5 patients; 20%) than ACNU-CDDP group (12 patients; 40%), while only 3 patients (9.6%) in RT group experienced grade 3 or 4 toxicities. CONCLUSION: An application of chemotherapy before or after radiotherapy is beneficial in prolonging the survival of patients with AA. Adjuvant PCV chemotherapy after radiotherapy is recommendable.
Astrocytoma ; Clinical Protocols ; Humans ; Lomustine ; Male ; Procarbazine ; Retrospective Studies ; Vincristine

OBJECTIVE: This retrospective study was performed to evaluate the role of chemotherapy in the management of patients with anaplastic astrocytoma (AA). METHODS: We compared the survival outcome among the 3 different treatment protocol groups in a single institution. A total of 86 patients (39 men and 47 women) with newly diagnosed AA after surgery were analyzed. Among them, 31 patients (36.0%) were treated with radiotherapy only (RT Group), 30 patients (34.9%) were treated with nimustine-cisplatin chemotherapy before RT (ACNU-CDDP group), and 25 patients (29.1%) were treated with procarbazine, lomustine and vincristine (PCV) chemotherapy after radiotherapy (PCV group). RESULTS: The median survival was 14.0, 30.0 and 72.0 months in RT, ACNU-CDDP, and PCV group, respectively and showed significant differences (RT vs. ACNU-CDDP; p=0.039, RT vs. PCV; 0.002, ACNU-CDDP vs. PCV; 0.045). PCV group showed less toxicity rate (5 patients; 20%) than ACNU-CDDP group (12 patients; 40%), while only 3 patients (9.6%) in RT group experienced grade 3 or 4 toxicities. CONCLUSION: An application of chemotherapy before or after radiotherapy is beneficial in prolonging the survival of patients with AA. Adjuvant PCV chemotherapy after radiotherapy is recommendable.
Astrocytoma ; Clinical Protocols ; Humans ; Lomustine ; Male ; Procarbazine ; Retrospective Studies ; Vincristine

A Case of primary malignant lymphoma in the uterine cervix of a 58-year-old multigravidwoman is reported. Primary malignant lymphoma localized in the uterine cervix is a rare condition.Previously, treatment of this disease has been radiation therapy, surgery or chemotherapyeither alone or in combination.We experienced one case of primary malignant lymphoma of the uterine cervix, stageI b according to FIGO, which was treated with radiation therapy and CHOP chemotherapy.The patient first underwent radiation therapy. This was followed by an chemotherapyconsisting of cyclophosphamide, adriamycin, vincristine, and prednisone.No evidence of recurrent lymphoma has been observed in 3 year after the treatment.
Cervix Uteri* ; Cyclophosphamide ; Doxorubicin ; Female ; Humans ; Lymphoma* ; Middle Aged ; Vincristine

The authors analyzed preliminary outcome of 10 patients with mixed glioma(3 patients with low-grade oligoastrocytoma and 7 patients with anaplastic oligoastrocytoma) who underwent surgical resection and were treated or are in treatment with or without adjuvant therapy at our institute since May 1993. In the low-grade oligoastrocytoma group, gross total tumor resection was done in all three cases and postoperative radiation therapy was performed in 2 cases. In the anaplastic oligoastrocytoma group, all seven cases were divided as to the amount of tumor removal(gross total resection; 4 cases, subtotal resection; 1 case, partial resection; 2 cases) and clinical course and prognosis were analyzed as to performing postoperative radiation therapy with or without chemotherapy. In the low-grade oligoastrocytoma group, one patient who didn't undergo postoperative radiation therapy suffered from tumor recurrence that showed histopathologically malignant transformation. In the anaplastic oligoastrocytoma group, 2 patients who underwent subtotal tumor resection and partial tumor resection with postoperative radiation therapy showed tumor progression and histopathologically more malignant transformation. The authors propose that gross total tumor resection with postoperative radiation therapy in low-grade oligoastrocytoma and adding chemotherapy(especially with procarbazine, lomustine, vincristine; PCV regimen) in anaplastic oligoastrocytoma appear to be associated with more prolongation of patient's survival.
Drug Therapy ; Glioma* ; Humans ; Lomustine ; Procarbazine ; Prognosis ; Recurrence ; Vincristine

No abstract available.
Drug Therapy, Combination* ; Melphalan* ; Multiple Myeloma* ; Prednisone* ; Vincristine*

Two cases of malignant histiocytosis, in which skin involvement was a prominent finding at initial clinical presentation, are reported. 1nteresting histopathologic findings, including Langerhans granule in one case and numerous eosinophils in another, were observed. In one case remission was achieved with BACOP chemotherapy (Bleomycin, Adriamycin, Cyclophosphamide, Vincristine, and Prednisone). In the other case, the patient died nine months after the onset of the disease without any treatment.
Cyclophosphamide ; Doxorubicin ; Drug Therapy ; Eosinophils ; Histiocytic Sarcoma* ; Humans ; Skin ; Vincristine